» Articles » PMID: 36868960

Guidelines for the Diagnosis, Treatment, Prevention and Control of Infections Caused by Carbapenem-resistant Gram-negative Bacilli

Abstract

The dissemination of carbapenem-resistant Gram-negative bacilli (CRGNB) is a global public health issue. CRGNB isolates are usually extensively drug-resistant or pandrug-resistant, resulting in limited antimicrobial treatment options and high mortality. A multidisciplinary guideline development group covering clinical infectious diseases, clinical microbiology, clinical pharmacology, infection control, and guideline methodology experts jointly developed the present clinical practice guidelines based on best available scientific evidence to address the clinical issues regarding laboratory testing, antimicrobial therapy, and prevention of CRGNB infections. This guideline focuses on carbapenem-resistant Enterobacteriales (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), and carbapenem-resistant Pseudomonas aeruginosa (CRPA). Sixteen clinical questions were proposed from the perspective of current clinical practice and translated into research questions using PICO (population, intervention, comparator, and outcomes) format to collect and synthesize relevant evidence to inform corresponding recommendations. The grading of recommendations, assessment, development and evaluation (GRADE) approach was used to evaluate the quality of evidence, benefit and risk profile of corresponding interventions and formulate recommendations or suggestions. Evidence extracted from systematic reviews and randomized controlled trials (RCTs) was considered preferentially for treatment-related clinical questions. Observational studies, non-controlled studies, and expert opinions were considered as supplementary evidence in the absence of RCTs. The strength of recommendations was classified as strong or conditional (weak). The evidence informing recommendations derives from studies worldwide, while the implementation suggestions combined the Chinese experience. The target audience of this guideline is clinician and related professionals involved in management of infectious diseases.

Citing Articles

[Chinese expert consensus on prevention and treatment of immunotherapeutic and molecular targeted agents-related infections in patients with hematological malignancies (2025)].

Zhonghua Xue Ye Xue Za Zhi. 2025; 46(1):18-30.

PMID: 40059678 PMC: 11886436. DOI: 10.3760/cma.j.cn121090-20241114-00451.


Pharmacodynamic target attainment of the synergism of ceftazidime-avibactam in combination with amikacin against OXA-producing extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa.

Kang Y, Cui J Eur J Clin Microbiol Infect Dis. 2025; .

PMID: 40056304 DOI: 10.1007/s10096-025-05090-z.


Investigating Gram-negative bacilli isolates' sensitivity to ceftazidime/avibactam.

Sunali , Jha M, Kumar M, Kumar M, Ranjan N J Family Med Prim Care. 2025; 14(1):311-316.

PMID: 39989554 PMC: 11844935. DOI: 10.4103/jfmpc.jfmpc_1272_24.


Whether to continue combining carbapenems to treat carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia in critically ill patients: a retrospective efficacy and safety analysis.

Shiqi C, Chuhui W, Yijing Z, Yulan Q, Jiaojiao C, Keyu C Eur J Clin Microbiol Infect Dis. 2025; .

PMID: 39955472 DOI: 10.1007/s10096-025-05063-2.


antimicrobial activity of nitroxoline against uropathogens isolated from China.

Yi X, Chen X, Lu Y, Zhang J, Chen J, Wang M JAC Antimicrob Resist. 2025; 7(1):dlaf012.

PMID: 39906358 PMC: 11791683. DOI: 10.1093/jacamr/dlaf012.